$182.05
-2.6%IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Chief Executive Officer & Chairman
Compensation
$5,786,243
Chief Human Resources Officer & Executive Vice President
Executive Vice President & Chief Financial Officer
Compensation
$2,207,406
Executive Vice President of Global Technology & Operations
Executive Vice President, General Counsel & Secretary
Compensation
$1,423,956
President of Commercial Solutions - IQVIA
Compensation
$1,014,564
President of Research & Development Solutions
Compensation
$1,744,347
SVice President of Investment Relation & Treasury
Senior Vice President, Corporate Controller & Chief Accounting Officer
Senior Vice President, Global Chief Medical & Scientific Officer
During the last 12 months, insiders have sold $11.10M worth of IQV shares, with no buying activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
36.6K
8.13M
-8.1M
-$8.13M
0
0.00
8.0K
1.76M
-1.8M
-$1.76M
0
0.00
6.3K
1.21M
-1.2M
-$1.21M
No buying activity
Bousbib Ari
Director, Officer: See Remarks
$9.01M
Sherbet Eric
Officer: See Remarks
$1.98M
Cherofsky Keriann
Officer: See Remarks
$105K
Strong bearish signal with $11.10M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
IQV - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | February 27, 2026 | April 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | February 28, 2025 | April 24, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | February 23, 2024 | April 16, 2024 | 2024 | |
DEF 14A DEF 14A N/A | February 27, 2023 | February 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | February 28, 2022 | April 12, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | February 26, 2021 | April 13, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | February 18, 2020 | April 06, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | February 21, 2019 | April 09, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | March 01, 2018 | April 10, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | February 22, 2017 | April 06, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.